title: Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept.
abstract: OBJECTIVE
  To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment.
  
  
  METHODS
  This was a prospective ongoing multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months.
  
  
  RESULTS
  In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter.
  
  
  CONCLUSIONS
  The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months.
authors.affiliation: Department of Paediatrics, Sp 1547, Erasmus MC Sophia Children's Hospital, PO Box 2060, 3000 CB Rotterdam, The Netherlands. m.otten@erasmusmc.nl
authors.forename: Marieke H
authors.initials: MH
authors.lastname: Otten
authors.forename: Femke H M
authors.initials: FH
authors.lastname: Prince
authors.forename: Marinka
authors.initials: M
authors.lastname: Twilt
authors.forename: Marion A J
authors.initials: MA
authors.lastname: van Rossum
authors.forename: Wineke
authors.initials: W
authors.lastname: Armbrust
authors.forename: Esther P A H
authors.initials: EP
authors.lastname: Hoppenreijs
authors.forename: Sylvia
authors.initials: S
authors.lastname: Kamphuis
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Koopman-Keemink
authors.forename: Nico M
authors.initials: NM
authors.lastname: Wulffraat
authors.forename: Simone L
authors.initials: SL
authors.lastname: Gorter
authors.forename: Rebecca
authors.initials: R
authors.lastname: Ten Cate
authors.forename: Lisette W A
authors.initials: LW
authors.lastname: van Suijlekom-Smit
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D009426:Netherlands; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept